Oral pioglitazone reduces infarction volume and improves neurologic function following MCAO in rats

8Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Thiazolidinediones (TZDs) are neuroprotective in rodent stroke models using intra-peritoneal, intra-venous and inter-ventricular routes of administration.We tested if oral pioglitazone at doses similar to those used by humans to treat diabetes reduces infarction volume following middle cerebral artery occlusion (MCAO) in the rat. Rats were fed DMSO or pioglitazone (0.65mg/kg equivalent to a 45mg dose in a 70kg man, 0.40mg/kg equivalent to a 30mg dose or 0.20mg/kg to a15mg dose) dissolved in DMSO daily for five days prior to 2 hour MCAO. Animals underwent serial functional analysis using the modified neurologic stroke scale (mNSS), the adhesive sticker test and the inclined plane, all of which test motor sensory function. Twenty one days later, MCAO rats were sacrificed and infarct volumes determined. We found significant reductions in the infarct volume using the 0.65 and 0.40mg/kg dose. Furthermore, these rats had improved performance on behavioural assays. The 0.20mg/kg dose did not significantly reduce infarction volume or improve behaviour. © 2011 Springer Science+Business Media, LLC.

Cite

CITATION STYLE

APA

Blankenship, D., Niemi, J., Hilow, E., Karl, M., & Sundararajan, S. (2011). Oral pioglitazone reduces infarction volume and improves neurologic function following MCAO in rats. In Advances in Experimental Medicine and Biology (Vol. 701, pp. 157–162). Springer New York LLC. https://doi.org/10.1007/978-1-4419-7756-4_22

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free